Risk Factors and Prognosis of Carbapenem-Resistant Organism Colonization and Infection in Acute Cholangitis

References

• Takada T, Strasberg SM, Solomkin JS, et al. TG13: updated Tokyo guidelines for the management of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20(1):1–7. doi:10.1007/s00534-012-0566-y
   PubMed Web of Science ®Google Scholar
• Yokoe M, Hata J, Takada T. Tokyo guidelines 2018: diagnostic criteria and severity grading of acute. J Hepatobiliary Pancreat Sci. 2018;25(1):41–54. doi:10.1002/jhbp515
   PubMed Web of Science ®Google Scholar
• Mayumi T, Okamoto K, Takada T, et al. Tokyo guidelines 2018: management bundles for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):96–100. doi:10.1002/jhbp.519
   PubMed Web of Science ®Google Scholar
• Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol. 2020;5(3):306–315. doi:10.1016/S2468-1253(19)30343-7
   PubMed Web of Science ®Google Scholar
• Sung YK, Lee JK, Lee KH, Lee KT, Kang CI. The clinical epidemiology and outcomes of bacteremic biliary tract infections caused by antimicrobial-resistant pathogens. Am J Gastroenterol. 2012;107(3):473–483. doi:10.1038/ajg.2011.387
   PubMed Web of Science ®Google Scholar
• Tanaka A, Leung PS, Gershwin ME. Pathogen infections and primary biliary cholangitis. Clin Exp Immunol. 2019;195(1):25–34. doi:10.1111/cei.13198
   Web of Science ®Google Scholar
• Tompkins K, van Duin D. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. Eur J Clin Microbiol Infect Dis. 2021;40(10):2053–2068. doi:10.1007/s10096-021-04296-1
   PubMed Web of Science ®Google Scholar
• Chamieh A, El-Hajj G, Zmerli O, Afif C, Azar E. Carbapenem resistant organisms: a 9-year surveillance and trends at Saint George University Medical Center. J Infect Public Health. 2020;13(12):2101–2106. doi:10.1016/j.jiph.2019.02.019
   PubMed Web of Science ®Google Scholar
• Sexton ME, Bower C, Jacob JT. Risk factors for isolation of carbapenem-resistant Enterobacterales from normally sterile sites and urine. Am J Infect Control. 2022;50(8):929–933. doi:10.1016/j.ajic.2021.12.007
   Web of Science ®Google Scholar
• O’Hara LM, Nguyen MH, Calfee DP, et al.; CDC Prevention Epicenters Program. Risk factors for transmission of carbapenem-resistant Enterobacterales to healthcare personnel gloves and gowns in the USA. J Hosp Infect. 2021;109:58–64. doi:10.1016/j.jhin.2020.12.012
   Web of Science ®Google Scholar
• Moghnieh R, Abdallah D, Jadayel M, et al. Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales. Sci Rep. 2021;11(1):1–4. doi:10.1038/s41598-021-94295-1
   Web of Science ®Google Scholar
• Zhou C, Jin L, Wang Q, et al. Bloodstream infections caused by Carbapenem-resistant Enterobacterales: risk factors for mortality, antimicrobial therapy and treatment outcomes from a prospective multicenter study. Infect Drug Resist. 2021;14:731. doi:10.2147/IDR.S294282
   PubMed Web of Science ®Google Scholar
• Routsi C, Pratikaki M, Platsouka E, et al. Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients. Intensive Care Med. 2013;39(7):1253–1261. doi:10.1007/s00134-013-2914-z
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69(Supplement_7):S521–8. doi:10.1093/cid/ciz824
   PubMed Web of Science ®Google Scholar
• Wu D, Chen C, Liu T, Jia Y, Wan Q, Peng J. Epidemiology, susceptibility, and risk factors associated with mortality in carbapenem-resistant gram-negative bacterial infections among abdominal solid organ transplant recipients: a retrospective cohort study. Infect Dis Ther. 2021;10(1):559–573. doi:10.1007/s40121-021-00411-z
   PubMed Web of Science ®Google Scholar
• Teo JQ, Chang CW, Leck H, et al. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: a case-control study. Int J Antimicrob Agents. 2019;53(5):657–662. doi:10.1016/j.ijantimicag.2019.03.011
   PubMed Web of Science ®Google Scholar
• Aleidan FAS, Alkhelaifi H, Alsenaid A, et al. Incidence and risk factors of carbapenem-resistant Enterobacteriaceae infection in intensive care units: a matched case-control study. Expert Rev Anti Infect Ther. 2021;19(3):393–398. doi:10.1080/14787210.2020.1822736
   PubMed Web of Science ®Google Scholar
• Tian S, Li K, Tang H, et al. Clinical characteristics of gram-negative and gram-positive bacterial infection in acute cholangitis: a retrospective observational study. BMC Infect Dis. 2022;22(1):1. doi:10.1186/s12879-021-06964-1
   Web of Science ®Google Scholar
• Morris CP, Bergman Y, Tekle T, Fissel JA, Tamma PD, Simner PJ. Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol. 2020;59(1):e01649–20. doi:10.1128/JCM.01649-20
   Web of Science ®Google Scholar
• Olalekan A, Onwugamba F, Iwalokun B, Mellmann A, Becker K, Schaumburg F. High proportion of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae among extended-spectrum β-lactamase-producers in Nigerian hospitals. J Glob Antimicrob Resist. 2020;21:8–12. doi:10.1016/j.jgar.2019.09.007
   Web of Science ®Google Scholar
• Sulzer JK, Ocuin LM. Cholangitis: causes, diagnosis, and management. Surg Clin. 2019;99(2):175–184. doi:10.1016/j.suc.2018.11.002
   Web of Science ®Google Scholar
• Aboelsoud M, Siddique O, Morales A, Seol Y, Al-Qadi M. Early biliary drainage is associated with favourable outcomes in critically-ill patients with acute cholangitis. Gastroenterol Rev. 2018;13(1):16–21. doi:10.5114/pg.2018.74557
   Google Scholar
• Carbone M, Milani C, Gerussi A, Ronca V, Cristoferi L, Invernizzi P. Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets. J Hepatol. 2020;73(4):965–966. doi:10.1016/j.jhep.2020.05.041
   Web of Science ®Google Scholar
• Lee JG. Diagnosis and management of acute cholangitis. Nat Rev Gastroenterol Hepatol. 2009;6(9):533–541. doi:10.1038/nrgastro.2009.126
   PubMed Web of Science ®Google Scholar
• Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet. 2020;396(10266):1915–1926.
   PubMed Web of Science ®Google Scholar
• Goodman KE, Simner PJ, Tamma PD, Milstone AM. Infection control implications of heterogeneous resistance mechanisms in. Expert Rev Anti Infect Ther. 2016;14(1):95–108. doi:10.1586/14787210.2016.1106940
   PubMed Web of Science ®Google Scholar
• Reyes S, Nicolau DP. Precision medicine for the diagnosis and treatment of carbapenem-resistant. Expert Rev Anti Infect Ther. 2020;18(8):721–740. doi:10.1080/14787210.2020.1760844
   PubMed Web of Science ®Google Scholar
• Kohler P, Fulchini R, Albrich WC, et al. Antibiotic resistance in Swiss nursing homes: analysis of national surveillance. Antimicrob Resist Infect Control. 2018;7(1):1–9.
   Google Scholar
• Nucleo E, Caltagirone M, Marchetti VM. Colonization of long-term care facility residents in three Italian provinces by. Antimicrob Resist Infect Control. 2018;7:33. doi:10.1186/s13756-018-0326-0
   Web of Science ®Google Scholar
• Warren DK, Guth RM, Coopersmith CM, Merz LR, Zack JE, Fraser VJ. Prevalence of methicillin-resistant Staphylococcus aureus colonization in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2006;27(10):1032–1040.
   Web of Science ®Google Scholar
• Amanati A, Sajedianfard S, Khajeh S. Bloodstream infections in adult patients with malignancy, epidemiology. BMC Infect Dis. 2021;21(1):636. doi:10.1186/s12879-021-06243-z
   Web of Science ®Google Scholar
• Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ. Virulence. 2017;8(4):391–402. doi:10.1080/2150559420161213472
   PubMed Web of Science ®Google Scholar
• Cheng VC, Chen JH, Ng WC, et al. Emergence of carbapenem-resistant Acinetobacter baumannii in nursing homes with. Infect Control Hosp Epidemiol. 2016;37(8):983–986. doi:10.1017/ice201684
   Web of Science ®Google Scholar
• Brugnaro P, Fedeli U, Pellizzer G, et al. Clustering and risk factors of methicillin-resistant Staphylococcus aureus. Infection. 2009;37(3):216–221.
   Web of Science ®Google Scholar
• Oka K, Matsumoto A, Tetsuka N. Clinical characteristics and treatment outcomes of carbapenem-resistant. J Glob Antimicrob Resist. 2022;29:247–252. doi:10.1016/j.jgar.2022.04.004
   Web of Science ®Google Scholar
• Mody L, Gibson KE, Horcher A, et al. Prevalence of and risk factors for multidrug-resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol. 2015;36(10):1155–1162. doi:10.1017/ice.2015.143
   Web of Science ®Google Scholar
• Freire MP, de Oliveira Garcia D, Lima SG, et al. Performance of two methods of carbapenem-resistant Enterobacterales surveillance. Infection. 2022;9:1–9. doi:10.1007/s15010-022-01839-2
   Web of Science ®Google Scholar
• Wang ZQ, Guo ZL, Feng H, et al. Treatment of donor-derived Carbapenem-resistant Klebsiella pneumoniae infection. Curr Med Sci. 2021;41(4):770–776.
   Web of Science ®Google Scholar
• Wang Z, Qian Y, Bai H, Yang J, Li X. Allograft hemorrhage as a manifestation of carbapenem-resistant Klebsiella pneumonia infection in kidney transplant recipients: case series. Medicine. 2020;99(13):1.
   Web of Science ®Google Scholar
• March A, Aschbacher R, Dhanji H. Colonization of residents and staff of a long-term-care facility and adjacent. Clin Microbiol Infect. 2010;16(7):934–944. doi:10.1111/j.1469-0691.2009.03024.x
   PubMed Web of Science ®Google Scholar